Drugs / CIK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02621333 | Oct 2015 → Sep 2018 | lung adenocarcinoma | Henan Cancer Hospital | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02621333 ↗ |
| Modality | Cell therapy | “about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.” NCT02621333 ↗ |
| Route | Intravenous | “about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.” NCT02621333 ↗ |